EMEDZ.NET

Disclaimer Notice:

Dear Readers! I started this blog when my daughter was in the NICU. She had ventriculitis. Her CSF report grew E.coli. But, she was injected Teicoplanin directly into her brain. The doctors made two errors here:

Teicoplanin is for gram-positive bacteria only. It does not treat E.coli.
Teicoplanin is not for intraventricular use. The manufacturer strongly discourage injecting Teicoplanin into the brain.

My daughter bled into the brain. She lived for another two years and ultimately died.

The information provided on Emedz.net is for doctors and pharmacists only to manage their patients in the best way and avoid medications-related errors.

Still, for the general population, this should not be considered professional medical advice or a substitute for consultation with a licensed healthcare provider. The content on this blog is not intended to diagnose, treat, cure, or prevent any disease or health condition.

Always seek the advice of a qualified healthcare professional before making any changes to your diet, exercise routine, medication, or any other aspect of your healthcare. We strongly discourage self-medication and self-treatment.

Even though the primary author of emedz.net is an experienced health professional, the blog is not intended to replace medical advice sought at the Doctor’s Clinic.

The authors share personal experiences, research findings, and general knowledge about health and wellness and medications-related topics.

However, individual health situations vary, and what works for one person may not work for another. It's important to consult with a healthcare provider for personalized guidance.

We strive to provide accurate and up-to-date information, but medical knowledge is constantly evolving. Therefore, we do not guarantee the accuracy, completeness, or timeliness of the information presented in this blog.

Emedz.net is not an online pharmacy:

Online pharmacies sell medicines and pharmaceutical products. EMEDZ.net is intended to provide drug-related information to pharmacists and physicians. It is intended to provide authentic information about medicines so as to prevent errors related to prescriptions.

We do not sell medicines, so please don’t ask for them.

We are not affiliated with any pharmaceutical companies:

Emedz.net has no affiliation with any pharmaceutical companies. We do not promote any product. Sometimes brand names are also mentioned in the title of the page, but that is what is called a “Featured Image”. It has nothing to do with selling or promoting that brand. Just to make things easier, generic and brands are mentioned in the blog.

Emedz.net may contain links to external websites or resources for your convenience. We do not endorse or take responsibility for the content of these external sites.

In no event shall Emedz.net, its authors, contributors, or any related parties be liable for any damages or consequences arising from the use of the information provided on this blog.

By using Emedz.net, you acknowledge and agree to this disclaimer and our Terms of Use. If you do not agree with this disclaimer or our Terms of Use, we advise you to refrain from using our website.

Remember, your health is a valuable asset, and decisions about your health should always be made in consultation with a qualified healthcare professional.

Chlorpheniramine for allergic symptoms, rhinitis, & urticaria

Chlorpheniramine is a first-generation anti-histamine that is used in the treatment of the following conditions:

Perennial and seasonal Allergic rhinitis, urticaria, and pruritus
Motion sickness

Chlorpheniramine Dose in Adults

Oral use in patients with Allergic symptoms, rhinitis, urticaria, and pruritus:

Immediate-release formulations:
- 4 mg 4 - 6 hourly (Maximum dose should not exceed 24 mg/day)
Extended-release tablets:
- 12 mg twice daily (The maximum dose should not exceed 24 mg/day)

Off-label use in Motion sickness:

Immediate-release tablets:
- 4 - 12 mg administered 3 hours prior to the inciting stimulus for motion sickness

Chlorpheniramine Dose in Childrens

Oral use for allergic symptoms and rhinitis

Immediate-release tablets and oral solutions:
- Children 2-6 years of age:
  - 1 mg 4 - 6 hourly to a maximum daily dose of 6 mg/day
- Children 6 - 11 years of age:
  - 2 mg 4-6 hourly to a maximum daily dose of 12 mg/day
- Children older than 12 years and Adolescents:
  - 4 mg 4 - 6 hourly to a maximum daily dose of 24 mg/day
Extended-Release tablets
- Children older than 12 years and Adolescents:
  - 12 mg twice daily to a maximum daily dose of 24 mg per day.

Pregnancy Risk Factor B

Its use in pregnancy has not been associated with birth defects and may be used in patients with rhinitis, urticaria, pruritis, and rash in pregnant women (Preferably use second-generation antihistamines)
To treat intrahepatic cholesterolemia of pregnancy, antihistamines should be avoided.

Use during breastfeeding:

It can be excreted in breastmilk, and can cause drowsiness or irritability in infants breastfed.
Breastfed infants need to be watched for irritability or drowsiness.
Furthermore, the newer generation antihistamines should be preferred over the first generation antihistamines.
Antihistamines can also reduce serum prolactin levels and milk production.

Chlorpheniramine Dose in Kidney Disease:

The manufacturer has not recommended any dose adjustment in patients with renal disease.

Chlorpheniramine Dose in Liver Disease:

The manufacturer has not recommended any dose adjustment in patients with liver disease.
However, since, it is metabolized by the liver, it should be used with caution.

Common Side Effects of Chlorpheniramine:

Central nervous system:
- Drowsiness (slight to moderate)
Respiratory:
- Thickening of bronchial secretions

Less Common Side Effects of Chlorpheniramine:

Central nervous system:
- Dizziness
- Excitability
- Fatigue
- Headache
- Nervousness
Endocrine & metabolic:
- Weight gain
Gastrointestinal:
- Abdominal pain
- Diarrhea
- Increased appetite
- Nausea
- Xerostomia
Genitourinary:
- Urinary retention
Neuromuscular & skeletal:
- Arthralgia
- Weakness
Ophthalmic:
- Diplopia
Renal:
- Polyuria
Respiratory:
- Pharyngitis

Contraindication to Chlorpheniramine:

Allergy to chlorpheniramine-maleate or any component of the formulation
Narrow-angle glaucoma
Bloat at the Bladder Outlet
Prostate hypertrophy symptoms
Acute asthmatic attacks
Peptic ulcer surgery
Pyloroduodenal obstruction
Due to the possibility of sudden infant death syndrome, avoid premature or term newborns.
Avoid using children's sleeping pills.

Warnings and Precautions

CNS depression:
- It can cause CNS depression and sedation that could lead to mental or physical impairments. It should be used with caution by patients who are required to maintain mental alertness for tasks.
Cardiovascular disease
- Patients suffering from cardiovascular disease such as hypertension or ischemic heart disease, should not take the drug.
Increased intraocular pressure
- May precipitate glaucoma. Patients with elevated intraocular pressure should not use it.
Prostatic hyperplasia and urinary obstruction:
- It can cause urinary retention in the elderly.
Respiratory disease
- When using the medication, those with asthma or chronic obstructive pulmonary disorders (COPD) should exercise caution.
Thyroid dysfunction:
- Patients with thyroid dysfunction should use it with caution.

Chlorpheniramine: Drug Interaction

Note: Drug Interaction Categories:

Risk Factor C: Monitor When Using Combination
Risk Factor D: Consider Treatment Modification
Risk Factor X: Avoid Concomitant Use

Risk Factor C (Monitor therapy).
Acetylcholinesterase inhibitors	Anticholinergic Agents may have a decreased therapeutic effect. Anticholinergic Agents can decrease the therapeutic effects of Acetylcholinesterase inhibitors.
Ajmaline	High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Alcohol (Ethyl)	CNS Depressants can increase the CNS depressant effects of Alcohol (Ethyl).
Alizapride	CNS Depressants may increase the CNS depressant effects.
Amantadine	Anticholinergic Agents may have an enhanced anticholinergic effect.
Amezinium	Amezinium may have a stronger stimulatory effect if it is combined with antihistamines.
Amphetamines	May lessen antihistamines' sedative effects.
Anticholinergic Agents	Other Anticholinergic Agents may have an adverse/toxic effect.
Betahistine	Betahistine's therapeutic effects may be diminished by antihistamines.
Botulinum Toxin-Containing Products	Anticholinergic Agents may have an enhanced anticholinergic effect.
Brexanolone	CNS Depressants can increase the CNS depressant effects of Brexanolone.
Brimonidine (Topical)	CNS Depressants may increase the CNS depressant effects.
Bromopride	CNS Depressants may increase the CNS depressant effects.
Cannabidiol	CNS Depressants may increase the CNS depressant effects.
Cannabis	CNS Depressants may increase the CNS depressant effects.
Chloral Betaine	Anticholinergic drugs could be harmful or poisonous.
Chlorphenesin Carbamate	CNS Depressants may have an adverse/toxic effect that can be exacerbated by them.
CloBAZam	High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
CNS Depressants	Can increase the toxic/adverse effects of CNS Depressants.
Cobicistat	High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Moderate CYP2D6 inhibitors	Might decrease metabolism of CYP2D6 substrates (High Risk with Inhibitors).
Darunavir	High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Dimethindene (Topical).	CNS Depressants may increase the CNS depressant effects.
Doxylamine	If taken alongside other CNS Depressants, CNS Depressants may have a stronger CNS depressing impact. Management: The producer of the pregnancy-safe drug Diclegis (doxylamine/pyridoxine) particularly advises against combining it with other CNS depressants.
Dronabinol	CNS Depressants may intensify the effects of CNS Depressants.
Esketamine	CNS Depressants may intensify the effects of CNS Depressants.
Fosphenytoin-Phenytoin	Chlorpheniramine may increase the serum concentration of Fosphenytoin-Phenytoin.
Gastrointestinal Agents (Prokinetic)	Anticholinergic Agents can reduce the therapeutic effects of Gastrointestinal Agents (Prokinetic).
Glucagon	Anticholinergic agents may increase the toxic/adverse effects of Glucagon. Particularly, there may be an increase in the likelihood of gastrointestinal adverse reactions.
HydrOXYzine	CNS Depressants may increase the CNS depressant effects.
Imatinib	High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Itopride	Itopride's therapeutic effects may be diminished by anticholinergic agents.
Kava Kava	CNS Depressants may have an adverse/toxic effect that can be exacerbated by them.
Lofexidine	CNS Depressants may have a greater depressant effect on the brain. Management: Separate drug interaction monographs are available for drugs listed as an exception to this monograph.
Lumefantrine	High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Magnesium Sulfate	CNS Depressants may increase the CNS depressant effects.
MetyroSINE	MetyroSINE may have a sedative effect that can be enhanced by CNS depressants.
Mianserin	Anticholinergic Agents may have an enhanced anticholinergic effect.
Minocycline	CNS Depressants may increase the CNS depressant effects.
Mirabegron	Anticholinergic agents may increase the toxic/adverse effects of Mirabegron.
Mirtazapine	CNS Depressants can increase the CNS depressant effects of Mirtazapine.
Nabilone	CNS Depressants may increase the CNS depressant effects.
Nitroglycerin	Anticholinergic medications may reduce Nitroglycerin's absorption. Anticholinergic drugs may slow down the sublingual nitroglycerin tablet's ability to dissolve, which could hinder or delay nitroglycerin absorption.
Panobinostat	High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Peginterferon Alfa-2b	Inhibitors carry a high danger. may reduce the levels of CYP2D6 substrates in serum. Serum levels of CYP2D6 Substrates may rise after administration of peginterferon Alf-2b.
Perhexiline	Perhexiline may be increased by CYP2D6 Substrates. Perhexiline can increase serum concentrations of CYP2D6 substrates (High Risk with Inhibitors).
Piribedil	CNS Depressants could increase the CNS depressant effects of Piribedil.
Pitolisant	Antihistamines can reduce the therapeutic effects of Pitolisant.
Pramipexole	Pramipexole may have a greater sedative effect if it is combined with CNS depressants.
QuiNINE	High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Ramosetron	Ramosetron's constipating effects may be enhanced by anticholinergic agents.
ROPINIRole	CNS Depressants can increase the sedative effects of ROPINIRole.
Rotigotine	CNS Depressants can increase the sedative effects of Rotigotine.
Rufinamide	CNS Depressants may have an adverse/toxic effect that can be exacerbated by this. Particularly, dizziness and sleepiness may be increased.
Selective Serotonin Reuptake inhibitors	CNS Depressants can increase the toxic/adverse effects of Selective Serotonin Resuptake Inhibitors. Particularly, psychomotor impairment could be increased.
Tetrahydrocannabinol	CNS Depressants may increase the CNS depressant effects.
Tetrahydrocannabinol, and Cannabidiol	CNS Depressants may increase the CNS depressant effects.
Thiazide and Thiazide - Like Diuretics	Anticholinergic Agents can increase serum Thiazide or Thiazide-Like Diuretics.
Topiramate	Topiramate's toxic/adverse effects may be exacerbated by anticholinergic agents.
Trimeprazine	CNS Depressants may intensify the effects of CNS Depressants.
Risk Factor D (Consider therapy modifications)
Abiraterone Acetate	High risk of Inhibitors causing an increase in serum concentrations of CYP2D6 substrates. When possible, avoid concurrent use of abiraterone and CYP2D6 Substrates with a narrow therapeutic index. If concurrent use cannot be avoided, closely monitor patients for signs and symptoms of toxic effects.
Asunaprevir	High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
BenzylpenicilloylPolylysine	Antihistamines may reduce BenzylpenicilloylPolylysine's ability to diagnose. Management: Delay testing until systemic antihistaminic effects have subsided and discontinue systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing. A histamine skin test can be used to check for lingering antihistaminic effects.
Blonanserin	CNS Depressants can increase the CNS depressant effects of Blonanserin.
Buprenorphine	CNS Depressants can increase the CNS depressant effects of buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Buprenorphine patches (Butrans) should be initiated at 5 mg/hr for adults when taken with other CNS depression drugs.
Chlormethiazole	CNS Depressants may increase the CNS depressant effects. Monitoring: Look out for signs of CNS depression. If a combination of chlormethiazole and other drugs is required, a reduced dose should be used.
Strong CYP2D6 inhibitors	Might decrease metabolism of CYP2D6 substrates (High Risk with Inhibitors).
Dacomitinib	High risk of Inhibitors causing an increase in serum concentrations of CYP2D6 substrates. Management: Do not use dacomitinib concurrently with CYP2D6 Substrates that have a narrow therapeutic Index.
Droperidol	CNS Depressants may increase the CNS depressant effects. Management: Droperidol and other CNS agents, such as opioids, may be reduced or used in combination with droperidol. Separate drug interaction monographs provide more detail on exceptions to this monograph.
Flunitrazepam	CNS Depressants can increase the CNS depressant effects of Flunitrazepam.
Hyaluronidase	Antihistamines may lessen the therapeutic effects of hyaluronidase. Treatment: Patients taking antihistamines, especially at larger doses, may not respond clinically to hyaluronidase at conventional doses. Hyaluronidase dosages may need to be increased.
HYDROcodone	CNS Depressants can increase the CNS depressant effects of HYDROcodone. When possible, avoid concomitant use with hydrocodone and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Methotrimeprazine	Methotrimeprazine may have a higher CNS depressant activity than CNS Depressants. Methotrimeprazine can increase the CNS depressant effects of CNS Depressants. Management: Lower the adult dose of CNS Depressants by 50% and start concomitant methotrimeprazine treatment. After clinically proven efficacy of methotrimeprazine, further CNS depressant dose adjustments should only be made.
Opioid Agonists	CNS Depressants can increase the CNS depressant effects of Opioid Aggonists. Management: When possible, avoid concomitant use opioid agonists and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
OxyCODONE	CNS Depressants can increase OxyCODONE's CNS depressant effects. When possible, avoid the simultaneous use of oxycodone and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Perampanel	CNS Depressants may have a greater CNS depressant effect. Perampanel and any other CNS depressant drug should be used in combination. Patients who take perampanel together with any other drug should not engage in complex or high-risk activities until they have had experience with the combination.
Pramlintide	Anticholinergic Agents may have an enhanced anticholinergic effect. These effects are only for the GI tract.
Secretin	Secretin's therapeutic effects may be diminished by anticholinergic agents. Concomitant use: Secretin and anticholinergic agents should be avoided. Stop using anticholinergic drugs for at least five half-lives before administering secretin.
Sodium Oxybate	CNS Depressants may have a greater depressant effect if taken in combination. Management: Look for alternatives to the combination use. If you must combine use, reduce the doses of any one or more drugs. It is not recommended to combine sodium oxybate and alcohol, or any sedative hypnotics.
Suvorexant	CNS Depressants can increase the CNS depressant effects of Suvorexant. Management: Suvorexant or any other CNS depressionant can be reduced in doses. Suvorexant should not be taken with alcohol. It is also not recommended to take suvorexant along with any other drugs for insomnia.
Tapentadol	CNS Depressants may increase the CNS depressant effects. Tapentadol, benzodiazepines and other CNS depressants should be avoided when possible. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Thioridazine	Thioridazine may have an arrhythmogenic effect that is enhanced by Chlorpheniramine. The serum concentration of Chlorpheniramine may be increased by Thioridazine. Management: If possible, avoid this combination. Monitor closely for arrhythmia and general toxicity of chlorpheniramine if you use it.
Zolpidem	CNS Depressants can increase the CNS depressant effects of Zolpidem. Management: For men who also take CNS depressants, reduce the adult Intermezzo brand sublingual Zolpidem dose to 1.75mg. For women, no dose adjustment is advised. Avoid using CNS depressants at night; do not use alcohol.
Risk Factor X (Avoid Combination)
Aclidinium	Anticholinergic Agents may have an enhanced anticholinergic effect.
Azelastine (Nasal	CNS Depressants could increase the CNS depressant effects of Azelastine.
Bromperidol	CNS Depressants may increase the CNS depressant effects.
Cimetropium	Cimetropium may have an anticholinergic effect that can be enhanced by the use of anticholinergic agents.
Eluxadoline	Eluxadoline may cause constipation by using anticholinergic agents.
Glycopyrrolate (Oral Inhalation)	Anticholinergic agents may increase the anticholinergic effects of Glycopyrrolate (Oral inhalation).
Glycopyrronium (Topical)	Anticholinergic Agents may have an enhanced anticholinergic effect.
Oral Inhalation with Ipratropium	Anticholinergic Agents may have an enhanced anticholinergic effect.
Levosulpiride	Anticholinergic Agents can reduce the therapeutic effects of Levosulpiride.
Orphenadrine	Orphenadrine may be more effective against CNS depression than other drugs.
Oxatomide	Anticholinergic Agents may have an enhanced anticholinergic effect.
Oxomemazine	CNS Depressants may increase the CNS depressant effects.
Paraldehyde	Paraldehyde may be enhanced by CNS depressants.
Potassium Chloride	Potassium Chloride may have an ulcerogenic effect that can be exacerbated by anticholinergic agents. Treatment: Patients taking drugs that have significant anticholinergic effects should not consume any oral dose form of potassium chloride.
Potassium Citrate	If potassium citrate is administered with anticholinergic drugs, it can increase the risk of ulcers.
Revefenacin	Revefenacin may be enhanced by anticholinergic agents.
Thalidomide	CNS Depressants can increase Thalidomide's CNS depressant effects.
Tiotropium	Anticholinergic agents may increase the anticholinergic effects of Tiotropium.
Umeclidinium	Anticholinergic Agents may have an enhanced anticholinergic effect.

Monitoring Parameters:

None required. Monitor symptoms control.

How to Administer Chlorpheniramine?

It may be administered with food or water.
When used for motion sickness, it should be administered 3 hours before the stimulus.
It should not be crushed or chewed and swallowed as a whole.

Mechanism of action of Chlorpheniramine:

It is an anti-allergic medication that works by competing with histamine receptors located in the gastrointestinal tract, blood vessels and respiratory tract.

It is 33%Protein-boundAndMetabolizedby the liver via CYP450 enzymes. It is aHalf-lifeThe time taken to reach the destination can vary from 6 to 24 hours.peak plasma concentrationIt takes between 1 and 6 hours.

It isexcretedPrimarily via urine

International Brands of Chlorpheniramine:

Aller-Chlor
Allergy Relief
Allergy
Allergy-Time
Chlor-Trimeton Allergy
Chlor-Trimeton
Ed Chlorped Jr
Ed ChlorPed
Ed-Chlortan
Pharbechlor
Acira
Ahiston
Alergidryl
Alergitrat
Aller
Allerfin
Allergex
Allermin
Allermine
Alleryl
Analer
Analerg
Anallerge
Antamin
Bregamin
Cadistin
Chlofen
Chloramine
Chlorohistal
Chlorohistan
Chlorohistol
Chlorpheniramine DHA
Chlorpheno
Chlorphenon
Chlorpyrimine
Chlortrimeton
Cipium
Clorfam
Cloro Trimeton
Cloro-Trimeton
Cloroalergan
Cohistan
Com-Trimeton
Derimeton
Histafen
Histal
Histalex
Histan
Histant
Histat
Histatapp
Histavil
Histon
Histop
Horamine
Isticol Jarabe
Lergisina
Lorecare
Nipolen
Niramine
Orphen
Peniramin
Pheneton 4
Pheniram
Piriton
Prodel
Sensitamine
Sprinsol
Trimeton
Valemine

Chlorpheniramine Brands in Pakistan:

Chlorpheniramine (Maleate) [Inj 10 mg/ml]
CHLOR	FRIENDS PHARMA (PVT) LTD
CHLORPHENIRAMINE	ORIENT LABORATORIES
CHLORPHENIRAMINE	GEOFMAN PHARMACEUTICALS
CHLORPHENIRAMINE	PLIVA PAKISTAN (PVT) LIMITED
HAMZIVIL	ELITE PHARMA

Chlorpheniramine(Maleate) [Syrup 2 mg/5ml]
ALLERGEX	NABIQASIM INDUSTRIES (PVT) LTD.
ALLERGON	MEDICRAFT PHARMACEUTICALS (PVT) LTD.
ALLERMINE	KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS
ALLERMINE	KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS
ALLERPHENE	P.D.H. PHARMACEUTICALS (PVT) LTD.
CEPIAM	ARDIN PHARMACEUTICALS
CHLORPHENIRAMINE	LISKO PAKISTAN (PVT) LTD
CHLORPHENIRAMINE	ORTA LABS. (PVT) LTD.
CHLORPHENIRAMINE	MIAN BROTHERS LABORATORIES (PVT) LTD.
CHLORPHENIRAMINE	KARACHI PHARMACEUTICAL LABORATORY
CHLORPHENIRAMINE	EROS PHARMACEUTICALS
CHLORPHENIRAMINE MALEATE	JAWA PHARMACEUTICALS(PVT) LTD.
COLEN	ALLIANCE PHARMACEUTICALS (PVT) LTD.
FENRAM	ALBRO PHARMA
HISTAGIC	LISKO PAKISTAN (PVT) LTD
HISTALON	POLYFINE CHEMPHARMA (PVT) LTD.
LOLRPHINE	NEUTRO PHARMA (PVT) LTD.
NIRMINE	DAVIS PHARMACEUTICAL LABORATORIES
PHEMIN	MARVI LABORATORIES
PHENAMINE	MUNAWAR PHARMA (PVT) LTD.
PHENERMIN	SEMOS PHARMACEUTICALS (PVT) LTD.
REPHENIRAMINE	SYNTEX PHARMACEUTICALS
RESMIN	RASCO PHARMA
RHINOL	IRZA PHARMA (PVT) LTD.
STAITON	STANDARD DRUG CO.
UNIHIST	UNISON CHEMICAL WORKS

Chlorpheniramin (Maleate) [Syrup 2.5 mg/5ml]
SYPRITON	SAYYED PHARMACEUTICALS

Chlorpheniramine (Maleate) [Tabs 4 mg]
ALLERMINE	KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS
ALLERPHENE	P.D.H. PHARMACEUTICALS (PVT) LTD.
ALLERVIL	INDUS PHARMA (PVT) LTD.
ALPHEM	ALSON PHARMACEUTICALS
APITON	EURO PHARMA INTERNATIONAL
BARITON	BATALA PHARMACEUTICALS.
CHLOFAMIN	ALFALAH PHARMA (PVT) LTD.
CHLOROPHENIRAMINE MALEATE	IRZA PHARMA (PVT) LTD.
CHLORPHENIRAMINE	KARACHI PHARMACEUTICAL LABORATORY
CHLORPHENIRAMINE	PHARMACARE LABORATORIES (PVT) LTD.
CHLORPHENIRAMINE	IDEAL PHARMACEUTICAL INDUSTRIES
CHLORPHENIRAMINE	MIAN BROTHERS LABORATORIES (PVT) LTD.
CHLORPHENIRAMINE	MUNAWAR PHARMA (PVT) LTD.
CHLORPHENIRAMINE	SEMOS PHARMACEUTICALS (PVT) LTD.
CHLORPHENIRAMINE	UNEXO LABS (PVT) LTD.
CHLORPHENIRAMINE	XENON PHARMACEUTICALS (PVT) LTD.
CHLORPHENIRAMINE	LISKO PAKISTAN (PVT) LTD
CHLORPHENIRAMINE	EROS PHARMACEUTICALS
CHLORPHENIRAMINE MALEATE	ARDIN PHARMACEUTICALS
CHLORPHENIRAMINE MALEATE	JAWA PHARMACEUTICALS(PVT) LTD.
CHLORPHENIRAMINE MALEATE	ETHICAL LABORATORIES (PVT) LTD.
DEEMINE	DELUX CHEMICAL INDUSTRIES
DHLORAMINE	KOHS PHARMACEUTICALS
FENAMINE	FLOW PHARMACEUTICALS (PVT) LTD.
FENRAM	ALBRO PHARMA
HARITON	HEALERS LABORATORIES
HISTAGIC	LISKO PAKISTAN (PVT) LTD
HISTAMOL	EPLA LABORATORIES (PVT) LTD.
HISTOM	KARACHI CHEMICAL INDUSTRIES
PHEMIN	MARVI LABORATORIES
PHENERMIN	SEMOS PHARMACEUTICALS (PVT) LTD.
PHENIR	VALOR PHARMACEUTICALS
PIRITON	GLAXOSMITHKLINE
REPHENIRAMINE	SYNTEX PHARMACEUTICALS
RESMIN	RASCO PHARMA
STAITON	STANDARD DRUG CO.

Chlorpheniramine (Maleate) [Tabs 10 mg]
CHLORPHENIRAMINE MALEATE	SHIFA LABORATORIES.(PVT) LTD.